Business Wire

Picsart Launches Marketing Studio to Help Businesses Create, Test and Run Google Ads

21.10.2026 16:03:00 CEST | Business Wire | Press Release

Share

Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today launched Marketing Studio, bringing content creation, advertising strategy, creative testing and paid distribution into one connected experience. Available now, Marketing Studio combines market insights from Zappi with a Google Ads integration that lets businesses create and launch campaigns directly within Picsart.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021274792/en/

Picsart, the AI Media Production Platform launches Marketing Studio - bringing content creation, advertising strategy, creative testing and paid distribution into one guided space. The new function includes hero partnerships with Google Ads and Zappi.

Built primarily for solopreneurs and small-business owners with limited marketing expertise, Marketing Studio helps answer four questions: where to invest, what to create, how to launch with the optimal creative assets and what is working. It also supports agencies producing more content against tight deadlines and performance marketers who need fresh creative to test.

Hovhannes Avoyan, Founder and CEO, Picsart, explains: “A small-business owner can know their product inside out and still struggle to communicate its value to customers. We build with our customers in mind, always looking for ways to help their creative efforts work harder for their business. That’s why expert guidance from AI agents at every stage of the marketing process is a core foundation of our new Marketing Studio.”

Further Detail on Picsart’s Marketing Studio

What does this mean for small businesses, solopreneurs and marketing teams?

Marketing Studio turns a business’s goals, product, market, competitors and audience into an advertising strategy. It provides guidance on where to invest, when to launch or scale campaigns, and when to maintain what is working. Businesses can create still images and video variations using Picsart’s video models and editing tools, with support for brand consistency as campaigns grow.

Picsart is introducing three new AI agents that can be found within Marketing Studio: Pax, a Google Ads Manager Agent; Draper, an Ad Strategist Agent; and Slava, a Performance Marketer and Campaign Manager. Together, they extend support from market research and advertising strategy through campaign management and paid distribution. Picsart continues to add new agents to its roster, expanding the specialized support available to creators, prosumers and businesses alike.

How does this compare to managing creative production and advertising separately?

Marketing Studio connects the steps between developing an idea and running a campaign. Through Picsart’s partnership with Zappi, the connected insights platform used by many of the world’s leading consumer brands including McDonald’s, PepsiCo and Vodafone, businesses can test concepts and videos before committing advertising spend. Recently launched, Vera, the agentic ad strategist, utilizes Zappi’s consumer insights and predictive technology to score creative, identify improvements and inform new video variations. In validation against hundreds of ads evaluated by real consumers, Zappi’s model identified stronger creative across key metrics 86–93% of the time.

The Google Ads integration lets businesses create and launch campaigns directly within Picsart, reducing the disconnected steps between production and distribution.

Mika Peterman, Strategic Partnerships & Business Development Leader, Google, adds: “Creative is the biggest driver of ad effectiveness. We’re thrilled to launch Google Ads within the Picsart platform to help their users easily turn high-quality assets into high-performing campaigns from a unified workflow. By bringing creation and distribution together, we're giving small businesses the tools to launch faster, iterate quickly based on real performance, and drive meaningful growth.”

Once campaigns are running, plain-language performance insights help businesses understand results and decide what to do next. Those findings feed back into creative production, helping teams refine concepts and generate new variations.

Marketing Studio is now available within Picsart.

Notes to Editors

About Picsart

Picsart is the AI-powered platform built for a content-first world. For more than 14 years, it has empowered the next generation of storytellers to create, scale and now monetize video content. Combining intuitive design tools, AI-powered image and video creation, and MCP and CLI functions, Picsart meets creators wherever they work. With more than 100 million monthly active users and over 2.5 billion downloads to date, Picsart is powering a new era of scalable, self-directed creativity, where content fuels identity, influence, and entrepreneurship.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021274792/en/

Contacts

For more information, please contact: press@picsart.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye